CPD-Accredited NMD4C Webinar | Up and Coming Stars in NMD | December 1st

Up and Coming Stars in NMD

Muscular Dystrophy Canada (MDC) and the Neuromuscular Disease Network for Canada (NMD4C) are pleased to invite you to a webinar on up and coming stars in NMD.
This webinar is primarily targeted at Canadian clinicians, academics and trainees with an interest in neuromuscular disease.

NMD4C and MDC are providing organizational and technical support, and this is an independent clinical/academic webinar with no industry sponsorship.
The NMD Rounds & Educational Webinars is a self-approved group learning activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.

Tuesday December 1st, 5:00pm -6:30pm EST

Register now! 

Agenda

Chair: Dr. Natasha Chang

Format: 4 x 20 min presentations (including questions) from early-career researchers and clinicians describing their journey to achieving their present position and provide an overview of their research.

Speakers:
1. Dr. Mireille Khacho (University of Ottawa): Shape-changing mitochondria: New players in muscle stem cell regulation
2. Dr. Gerald Pfeffer (University of Calgary): Alternative approaches to diagnosis of neurogenetic diseases
3. Dr. Élise Duchesne (Université du Québec à Chicoutimi): The skeletal muscle under a multifaced perspective
4. Dr. Natasha Chang (McGill University): Muscle stem cells and their contribution to DMD

Learning Objectives:
1. Engage with early career investigators and learn how they obtained independent academic positions
2. Learn how early career investigators are tackling neuromuscular diseases
3. Opportunity to ask questions regarding their academic career paths or research programs

If you have any questions, please email 

Oct_webinar title

Read next...

AGAMREE (vamorolone) Approved treatment for DMD in Canada

A Milestone in Neuromuscular Care: AGAMREE® (vamorolone) Approved as the First Treatment for Duchenne Muscular Dystrophy in Canada

Health Canada has approved AGAMREE® (vamorolone), the first-ever treatment for Duchenne Muscular Dystrophy (DMD) in Canada. Patient Support Program opens for enrollment on October 10, 2025.

Website - SBMA published on CMAJ.png

New Best Practice Recommendations for SBMA Care in Canada

Congratulations to Dr. Kerri Schellenberg, the team of Canadian experts, NMD4C Steering Committee members and Investigators, on publishing the first Canadian SBMA care guidelines!

2025 NMD4C ANNUAL MEETING

Advancing Neuromuscular Research and Care: Highlights from the 2025 NMD4C Annual Meeting

On September 11, NMD4C hosted its 2025 Annual Meeting in Ottawa, bringing together clinicians, researchers, trainees, and partners for a full day of collaboration, strategic dialogue, and community-building.

2025 Clinical Summer School

NMD4C Hosts Inaugural Clinical Summer School to Empower Canada’s Future Neuromuscular Leaders

On September 10–11, NMD4C hosted its inaugural Clinical Summer School in Ottawa, bringing together 19 neuromuscular clinical fellows from across Canada for two days of hands-on training, mentorship, and networking. Led by national experts and co-chaired by Drs. Gordon Jewitt and Marianne Nury, the program complemented NMD4C’s accredited lecture series and fostered peer connection through dedicated community-building sessions.

2026 Neuromuscular Postdoc Research Fellowship Competition

2026 Neuromuscular Postdoctoral Research Fellowships Funding Competition is Now Open!

Apply Or Share this opportunity with the trainees in your network — Deadline: October 14, 2025. Hosted by Neuromuscular Disease Network for Canada (NMD4C) and Muscular Dystrophy Canada (MDC)

Clinical Fellowship Awardees

Announcing the 2026 Neuromuscular Clinical Fellowship Award Recipients

We are excited to share that the 2026 Neuromuscular Clinical Fellowship Awards have been awarded! These fellowships strengthen clinical training in neuromuscular medicine and help prepare the next generation of specialists who will advance neuromuscular care across Canada.